AstraZeneca Pharma India surrenders marketing authorisation for Olaparib 100mg and 150mg
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
More than 40 types of Amyloid proteins are discovered till date
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
The supply of these goods is set to commence within the first quarter of FY26
Subscribe To Our Newsletter & Stay Updated